Yamano, Y., Takemura, M., Longshaw, C., & Echols, R. (2020). 1269. Differences in Interpretative Breakpoints Between CLSI, FDA and EUCAST Impact Reporting of Susceptibility and Resistance to Cefiderocol. Open Forum Infect Dis.
Citação norma ChicagoYamano, Yoshinori, Miki Takemura, Christopher Longshaw, and Roger Echols. "1269. Differences in Interpretative Breakpoints Between CLSI, FDA and EUCAST Impact Reporting of Susceptibility and Resistance to Cefiderocol." Open Forum Infect Dis 2020.
Citação norma MLAYamano, Yoshinori, Miki Takemura, Christopher Longshaw, and Roger Echols. "1269. Differences in Interpretative Breakpoints Between CLSI, FDA and EUCAST Impact Reporting of Susceptibility and Resistance to Cefiderocol." Open Forum Infect Dis 2020.